FINSBURY WORLDWIDE PHARMACEUTICALTRUST PLC
APPOINTMENT OF NEW DIRECTORS
The Board of the Company is delighted to announce the appointment of two new
directors to the Company with immediate effect.
Dr David Holbrook, is a qualified physician and Life Sciences Partner at MTI
Partners Limited, a leading technology venture capital investor. He attended
London and Oxford Universities, and has an MBA from Harvard Business School. He
has held senior positions in a number of blue-chip biopharmaceutical
organisations including GlaxoSmithKline and Roche.
Martin Smith, is a non executive director of New Star Asset Management Group
PLC. He attended Oxford University and has an MBA from Stanford University. He
was a founder of Phoenix Securities, a private investment banking firm.
Following the acquisition of Phoenix in 1997 by Donaldson Lufkin and Jenrette
(DLJ), he chaired DLJ's European Investment Banking Group. Previously he worked
at Citicorp and Bankers Trust.
There are no matters to be disclosed under listing rule 9.6.13.
For and on behalf of the Board
Frostrow Capital LLP
Company Secretary
8 November 2007
For further information please contact:
Ian Ivory, Chairman, Finsbury Worldwide Pharmaceutical Trust PLC 01828 640383
Alastair Smith, Frostrow Capital LLP 0203 008 4911
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.